Veristat, LLC

@VeristatCRO

Full-service CRO | Let's spend August learning more about & !

Vrijeme pridruživanja: studeni 2014.

Tweetovi

Blokirali ste korisnika/cu @VeristatCRO

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @VeristatCRO

  1. prije 14 sati

    Get an understanding of Expedited Pathways for accelerating time-to-market for products treating serious conditions or unmet medical needs from Veristat experts. Learn how.

    Poništi
  2. 4. velj

    When Do You Begin Planning Your Investigational New Drug Application (IND)? - Massachusetts Biotechnology Council

    Poništi
  3. proslijedio/la je Tweet
    31. sij

    In the pre-clinical stage of development, when should sponsors begin thinking about & planning for activities? Find out in our guest blog with :

    Poništi
  4. 17. sij

    View the on-demand webinar to learn about which considerations in your clinical trial database design may shorten or lengthen time-to-market. View now.

    Poništi
  5. 15. sij

    Do you understand the benefits and qualifying criteria for six different expedited programs and designations? Learn about Fast Track, Breakthrough Designation, QIDP, RMAT, and more. Get now.

    Poništi
  6. proslijedio/la je Tweet
    13. sij
    Poništi
  7. 9. sij

    Learn what new draft Guidance was published and drafted in December 2019. Read Veristat's Regulatory Guidance Monthly Review for December 2019.

    Poništi
  8. proslijedio/la je Tweet
    7. sij
    Poništi
  9. proslijedio/la je Tweet
    7. sij

    Congrats on the acquisition Wishing you & your team much success in 2020

    Poništi
  10. 8. sij

    Are you taking advantage of Expedited programs that were designed to speed the availability of new therapies to patients with serious conditions or unmet medical needs? Learn more.

    Poništi
  11. proslijedio/la je Tweet
    6. sij

    . enhances European foothold, closing acquisition of offer full-service support for global clinical studies; look to reveal synergies & new opportunities

    Poništi
  12. 6. sij

    Veristat strengthens its European presence and expands therapeutic expertise with the acquisition of the TCTC Group. Read the press release for more details around our expanded capabilities:

    Poništi
  13. 3. sij

    Is getting your product to market faster one of your new year’s resolutions? Consider using an expedited pathway to gain support for your development approach from ? View this infographic to learn about the types of expedited pathways.

    Poništi
  14. 2. sij

    Did you miss this exciting news over the holidays? Catalyst and Veristat join forces to create the most strategic team of regulatory experts to guide product development. Learn more now.

    Poništi
  15. 31. pro 2019.

    Wishing you a year of success in 2020! We look forward to continuing to help our biopharmaceutical clients bring new therapies to market in the new year!

    Poništi
  16. 23. pro 2019.

    Would having the most experienced regulatory team to develop and implement your regulatory strategy help fast track your clinical trials? Veristat has just amassed the premier team to help. Learn more.

    Poništi
  17. 20. pro 2019.

    Veristat wishes you a Happy Holiday Season and a Happy New Year!

    Poništi
  18. 19. pro 2019.

    Two like-minded teams of regulatory experts come together - Veristat and Catalyst Regulatory Services. Delivery of competent/proficient regulatory consulting, submissions and publishing solutions. Read how.

    Poništi
  19. 18. pro 2019.

    You can improve efficiency by selecting the right EDC system. Read the interview with Kathleen Boruchowski to learn how.

    Poništi
  20. 17. pro 2019.

    Did you hear? Veristat and Catalyst Regulatory Services have joined forces creating an unrivaled team of experts. Learn more.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·